Verma A, Palaniswamy K, Cremonini G, Heaton N, Dhawan A
Institute of Liver Studies, King's College Hospital, London, UK.
Pediatric Liver, GI and Nutrition and Institute of Liver Studies, King's College Hospital, London, UK.
Pediatr Transplant. 2017 May;21(3). doi: 10.1111/petr.12879. Epub 2017 Jan 30.
The complications and outcome associated with late CMV infection and disease on the graft are poorly characterized in PLT recipients. We studied the overall incidence, risk factors, and outcome of late CMV infection and disease (infection 6 months after transplant) in 180 PLT recipients admitted between 2008 and 2011 at the King's College Hospital. Antiviral prophylaxis of intravenous ganciclovir was given only to the D+R- group starting at day 7 post-transplant. The remaining groups (D-R+, D+R+, and D-R-) received pre-emptive therapy when they have CMV viremia above cut-off value and treatment for symptomatic CMV infection. The overall incidence of late CMV infection and disease was 9.4% (19/180) and 14.5% (19/130) in D+R-, D-R+, D+R- groups. The D-R+ group had the highest incidence of hepatitis (37.5%) and significantly increased incidence of CMV disease, and single and multiple acute rejection episodes when compared to the D+R- group, which received prophylaxis. The late CMV infection and disease in pediatric LT recipients was comparable to adult LT recipients despite variable duration of antiviral prophylaxis. Our results show that D-R+ group had highest rate of hepatitis and rejection episodes, associated with high morbidity, and should be considered for antiviral prophylaxis.
在血小板(PLT)受体中,晚期巨细胞病毒(CMV)感染及其相关疾病对移植物的影响尚不明确。我们研究了2008年至2011年间入住国王学院医院的180名PLT受体中晚期CMV感染及疾病(移植后6个月感染)的总体发病率、危险因素及预后情况。仅对D+R-组从移植后第7天开始给予静脉注射更昔洛韦进行抗病毒预防。其余组(D-R+、D+R+和D-R-)在CMV病毒血症高于临界值时接受抢先治疗,并对有症状的CMV感染进行治疗。在D+R-、D-R+、D+R-组中,晚期CMV感染及疾病的总体发病率分别为9.4%(19/180)和14.5%(19/130)。与接受预防治疗的D+R-组相比,D-R+组肝炎发病率最高(37.5%),CMV疾病、单次及多次急性排斥反应的发病率显著增加。尽管抗病毒预防的持续时间不同,但小儿肝移植(LT)受体中的晚期CMV感染及疾病情况与成人LT受体相当。我们的结果表明,D-R+组肝炎和排斥反应发生率最高,发病率高,应考虑进行抗病毒预防。